RAS-targeted cancer therapy: Advances in drugging specific mutations

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Rat sarcoma (RAS) proteins are frequently mutated oncogenes driving cancer, historically considered
• undruggable" targets.
• Recent success with KRAS G12C inhibitors marks a breakthrough, but efficacy varies across RAS mutations and cancers.
• Understanding diverse RAS allelic mutations is essential for developing effective cancer treatments.

Purpose of the Study:

• To review and compare structural and biochemical features of various RAS mutations.
• To summarize pathological characteristics and clinical treatment responses for cancers with RAS mutations.
• To provide an overview of current and emerging RAS inhibitor development strategies.

Main Methods:

• Literature review and synthesis of structural and biochemical data on RAS mutations.
• Compilation and analysis of clinical reports on cancer pathology and treatment outcomes.
• Survey of direct and indirect RAS inhibitor development targeting the RAS pathway.

Main Results:

• Detailed comparison of structural and biochemical properties across different RAS allelic mutations.
• Catalog of clinical data linking specific RAS mutations to cancer types and treatment responses.
• Summary of progress in developing both direct RAS inhibitors and indirect pathway modulators.

Conclusions:

• Deepening the understanding of RAS mutation characteristics is key to overcoming therapeutic variability.
• Further research into allele-specific RAS inhibitors is warranted for improved cancer treatment outcomes.
• This review provides a foundation for future RAS-targeting drug discovery and clinical application.